Ferric Carboxymaltose ( FCM )–Associated Hypophosphatemia ( HPP ): A Systematic Review
American Journal of Hematology · 2025-05 · 100 (5) · 840-846
DOI: 10.1002/ajh.27598 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Hematology, online erschienen am 11.02.2025. Verfasst von Joseph Magagnoli und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Southern Network on Adverse Reactions (SONAR), Clinical Pharmaceutical Outcomes Sciences Department, University of South Carolina College of Phar…. Hauptthemen laut MEDLINE: Ferric Compounds, Maltose, Hypophosphatemia. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SMT Inc.
Abstract (Originalsprache)
Background
Since 2015, ferric carboxymaltose (FCM), an intravenous (IV) iron formulation used for treating iron deficiency anemia (IDA), has been associated with an increasing number of reported hypophosphatemia (HPP) cases. Information on HPP clinical manifestations and incidence has not been reviewed.
Methods
We reviewed HPP‐associated adverse events reported to the FDA, case reports, case series, observational databases, clinical trials, meta‐analyses, and FDA‐approved labels. Our analysis found that FCM‐associated HPP is a clinically important adverse drug reaction (ADR). The most common clinical manifestations are general weakness, fatigue, bone pain, muscle pain, osteomalacia, and fractures. Information on rates of FCM‐associated HPP was from a review of clinical trials, observational databases, systematic reviews, and meta‐analyses.
Results
Clinical trials comparing FCM with other IV iron preparations identified FCM‐associated HPP rates between 50% and 92% versus 2% and 8% with other IV iron formulations. Meta‐analyses and systematic reviews confirmed these numbers. FDA‐approved FCM labels do not include details of available ADR information in case reports, case series, observational databases, randomized trials, and meta‐analyses.
Conclusion
We conclude that although the FDA‐approved FCM Prescribing Label was updated in 2023, more robust recommendations on FCM‐associated HPP are needed to prevent negative outcomes including osteomalacia and fractures. For patient safety, FCM label should advise monitoring serum phosphate levels prior to initiating first doses and before subsequent doses for all patients. Given differences between the FDA‐approved FCM label and data reviewed herein, clinicians must be educated about FCM‐associated HPP, difficulties treating HPP cases, and should consider administering other IV iron formulations that have lower rates of HPP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Southern Network on Adverse Reactions (SONAR), Clinical Pharmaceutical Outcomes Sciences Department, University of South Carolina College of Pharmacy, Columbia, South Carolina, USA.
- The Division of Hematology/Oncology of the Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Med…
ORCID-Profile: Charles L Bennett
Förderung
- SMT Inc
Zitieren
APA
Magagnoli, J., Knopf, K., Hrushesky, W. J., Carson, K. R., & Bennett, C. L. (2025). Ferric Carboxymaltose ( FCM )–Associated Hypophosphatemia ( HPP ): A Systematic Review. American Journal of Hematology, 100(5), 840-846. https://doi.org/10.1002/ajh.27598
Vancouver
Magagnoli J, Knopf K, Hrushesky WJ, Carson KR, Bennett CL. Ferric Carboxymaltose ( FCM )–Associated Hypophosphatemia ( HPP ): A Systematic Review. American Journal of Hematology. 2025;100(5):840-846. doi:10.1002/ajh.27598
BibTeX
@article{Magagnoli2025,
author = {Magagnoli, Joseph and Knopf, Kevin and Hrushesky, William J and Carson, Kenneth R and Bennett, Charles L},
title = {Ferric Carboxymaltose ( FCM )–Associated Hypophosphatemia ( HPP ): A Systematic Review},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {5},
pages = {840--846},
doi = {10.1002/ajh.27598}
}
EUVIMED